can you take semaglutide with one kidney use tied to lower disease risk in obesity How GLP-1s impact the heart

In a prespecified time-to-benefit secondary analysis presented at the European Congress on Obesity in 2025 and subsequently published, semaglutide produced a nominally significant reduction in MACE within the first 3 months (HR 0.63, 95% CI 0.410.95) and the first 6 months (HR 0.60, 95% CI 0.440.81), with curve separation visible within approximately 3 weeks of randomization [25], [26]

J., Gnzle, M., Cotter, P

4 Bioactive ginsenosides in metabolic and inflammatory liver disorders Non-alcoholic fatty liver disease (NAFLD) can progress to a more severe stage called NASH, which involves inflammation and liver scarring

doi: 10.1038/s41467-021-22938-y 100 ZhaoLZhangFDingXWuGLamYYWangXet al